Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $60.00$45.00 | $9.00/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| HYDROD7PH63M | Nov 2025 | 99.7% | Janoshik Analytical | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Hydro Research Peptides sell GHK-Cu?
Yes — Hydro Research Peptides currently lists GHK-Cu in 1 variant starting at $45.00 ($9.00/mg).
Is Hydro Research Peptides's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Hydro Research Peptides's GHK-Cu, with the most recent showing 99.7% purity. Hydro Research Peptides holds an overall trust grade of C (77/100) across all 78 COAs on file.
What is Hydro Research Peptides's trust grade for GHK-Cu?
Hydro Research Peptides has an overall Disclosed Labs trust grade of C (77/100), computed from 78 COAs across all peptides. The most recent GHK-Cu COA was issued by Janoshik Analytical.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Hydro Research Peptides's listing at $9.00/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| GHKCU-1001 | Mar 2024 | — | Janoshik Analytical | Endotoxin | Confirmed | View |
Disclosed Labs